Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2017

Open Access 01-12-2017 | Case Report

Sarcomatoid hepatocellular carcinoma (SHC): a case report

Authors: Yingying Yu, Yanping Zhong, Jingyu Wang, Di Wu

Published in: World Journal of Surgical Oncology | Issue 1/2017

Login to get access

Abstract

Background

Sarcomatoid hepatocellular carcinoma (SHC) is a rare malignant hepatic tumor. Recurrent interventional therapies such as transcatheter arterial chemo-embolization (TACE), radiofrequency ablation (RFA), and percutaneous ethanol injection have been reported previously utilized in a majority of SHC cases. To date, the exact pathogenic mechanisms underlying sarcomatoid transformation of hepatocellular carcinoma (HCC) remain unknown.

Case presentation

In this study, we report a 68-year-old female SHC patient admitted to our hospital due to discrete abdominal distention for more than 20 days. Abdominal computed tomography (CT) with tri-phase enhancement revealed portal vein tumor thrombi (PVTT) and a left hepatic lobe lesion measuring 110.0 mm × 160.0 mm. The patient subsequently underwent liver resection, after which pathological examination revealed proliferation of spindle-shaped SHC cells. A sarcomatoid, T4 stage carcinoma was eventually diagnosed. Forty-seven days after the operation, tri-phase enhanced CT detected extensive lesions in the liver, spleen, peritoneum, omentum majus, and mesentery, indicating SHC recurrence and metastases. Combination chemotherapy with pirarubicin and cisplatin was initiated for 1 cycle, but terminated due to resultant severe myelosuppression and medication intolerance. The patient was lost to therapy after 3 months of follow-up.

Conclusions

This case is unique because of hepatitis C virus infection. We should consider the possibility of this disease in patients with atypical clinical presentation.
Literature
1.
go back to reference Kojiro M, Sugihara S, Kakizoe S, Nakashima O, Kiyomatsu K. Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy. Cancer Chemother Pharmacol. 1989;23:4–8.CrossRef Kojiro M, Sugihara S, Kakizoe S, Nakashima O, Kiyomatsu K. Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy. Cancer Chemother Pharmacol. 1989;23:4–8.CrossRef
2.
go back to reference Nonnis R, Paliogiannis P, Giangrande D, Marras V, Trignano M. Low-grade fibromatosis-like spindle cell metaplastic carcinoma of the breast: a case report and literature review. Clin Breast Cancer. 2012;12:147–50.CrossRefPubMed Nonnis R, Paliogiannis P, Giangrande D, Marras V, Trignano M. Low-grade fibromatosis-like spindle cell metaplastic carcinoma of the breast: a case report and literature review. Clin Breast Cancer. 2012;12:147–50.CrossRefPubMed
3.
go back to reference Chrysikos D, Zagouri F, Sergentanis TN, et al. Mucinous tubular and spindle cell carcinoma of the kidney: a case report. Case Rep Oncol. 2012;5:347–53.CrossRefPubMedPubMedCentral Chrysikos D, Zagouri F, Sergentanis TN, et al. Mucinous tubular and spindle cell carcinoma of the kidney: a case report. Case Rep Oncol. 2012;5:347–53.CrossRefPubMedPubMedCentral
5.
go back to reference Giunchi F, Vasuri F, Baldin P, et al. Primary liver sarcomatous carcinoma: report of two cases and review of the literature. Pathol Res Pract. 2013;209:249–54.CrossRefPubMed Giunchi F, Vasuri F, Baldin P, et al. Primary liver sarcomatous carcinoma: report of two cases and review of the literature. Pathol Res Pract. 2013;209:249–54.CrossRefPubMed
6.
go back to reference Marijon H, Dokmak S, Paradis V, Zappa M, Bieche I, Bouattour M, Raymond E, Faivre S. Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma. J Hepatol. 2011;54:1073–8.CrossRefPubMed Marijon H, Dokmak S, Paradis V, Zappa M, Bieche I, Bouattour M, Raymond E, Faivre S. Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma. J Hepatol. 2011;54:1073–8.CrossRefPubMed
7.
go back to reference Kojiro M, Sugihara S, Kakizoe S, Nakashima O, Kiyomatsu K. Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy. Cancer Chemothe Pharmacolo. 1989;23:s4–8.CrossRef Kojiro M, Sugihara S, Kakizoe S, Nakashima O, Kiyomatsu K. Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy. Cancer Chemothe Pharmacolo. 1989;23:s4–8.CrossRef
8.
go back to reference Obara K, Matsumoto N, Okamoto M, Kobayashi M, Ikeda H, Takahashi H, et al. Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma. Hepatol Int. 2008;2:116–23.CrossRefPubMedPubMedCentral Obara K, Matsumoto N, Okamoto M, Kobayashi M, Ikeda H, Takahashi H, et al. Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma. Hepatol Int. 2008;2:116–23.CrossRefPubMedPubMedCentral
9.
go back to reference Nakanishi C, Sato K, Ito Y. Combined hepatocellular carcinoma and neuroendocrine carcinoma with sarcomatous change of the liver after transarterial chemoembolization. Hepatol Res. 2012;42:1141–5.CrossRefPubMed Nakanishi C, Sato K, Ito Y. Combined hepatocellular carcinoma and neuroendocrine carcinoma with sarcomatous change of the liver after transarterial chemoembolization. Hepatol Res. 2012;42:1141–5.CrossRefPubMed
10.
go back to reference Jarnagin WR, Weber S, Tickoo SK, Koea JB, Obiekwe S, Fong Y, DeMatteo RP, Blumgart LH, Klimstra D. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer. 2002;94:2040–6.CrossRefPubMed Jarnagin WR, Weber S, Tickoo SK, Koea JB, Obiekwe S, Fong Y, DeMatteo RP, Blumgart LH, Klimstra D. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer. 2002;94:2040–6.CrossRefPubMed
11.
go back to reference Lee WS, Lee KW, Heo JS, Kim SJ, Choi SH, Kim YI, Joh JW. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today. 2005;36:892–7.CrossRef Lee WS, Lee KW, Heo JS, Kim SJ, Choi SH, Kim YI, Joh JW. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today. 2005;36:892–7.CrossRef
12.
go back to reference Ishak KG, Anthony PP, Nicederau C, Nakanuma Y. Mesenchymal tumours of the liver. In: Stanley RH, Lauri AA, editors. WHO international histological classification of tumours, pathology and genetics of the tumours of the digestive system. Lyon: IARC Press; 2000. p. 191–8. Ishak KG, Anthony PP, Nicederau C, Nakanuma Y. Mesenchymal tumours of the liver. In: Stanley RH, Lauri AA, editors. WHO international histological classification of tumours, pathology and genetics of the tumours of the digestive system. Lyon: IARC Press; 2000. p. 191–8.
13.
go back to reference Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.CrossRefPubMed Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.CrossRefPubMed
14.
go back to reference Battaglia S, Benzoubir N, Nobilet S, Charneau P, Samuel D, Zignego AL, Atfi A, Bréchot C, Bourgeade MF. Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumour suppression to epithelial-mesenchymal transition. PLoS One. 2009;4:e4355.CrossRefPubMedPubMedCentral Battaglia S, Benzoubir N, Nobilet S, Charneau P, Samuel D, Zignego AL, Atfi A, Bréchot C, Bourgeade MF. Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumour suppression to epithelial-mesenchymal transition. PLoS One. 2009;4:e4355.CrossRefPubMedPubMedCentral
15.
go back to reference Koo HR, Park MS, Kim MJ, et al. Radiological and clinical features of sarcomatoid hepatocellular carcinoma in 11 cases. J Comput Assist Tomogr. 2008;32:745–9.CrossRefPubMed Koo HR, Park MS, Kim MJ, et al. Radiological and clinical features of sarcomatoid hepatocellular carcinoma in 11 cases. J Comput Assist Tomogr. 2008;32:745–9.CrossRefPubMed
16.
go back to reference Amarapurkar AD, Vibhav, Kim V. Angiogenesis in liver cirrhosis and hepatocellular carcinoma. Indian J Pathol Microbiolo. 2008;51:323–8.CrossRef Amarapurkar AD, Vibhav, Kim V. Angiogenesis in liver cirrhosis and hepatocellular carcinoma. Indian J Pathol Microbiolo. 2008;51:323–8.CrossRef
17.
go back to reference Hwang S, Lee SG, Lee YJ, et al. Prognostic impact of sarcomatous change of hepatocellular carcinoma in patients undergoing liver resection and liver transplantation. J Gastrointest Surg. 2008;12:718–24.CrossRefPubMed Hwang S, Lee SG, Lee YJ, et al. Prognostic impact of sarcomatous change of hepatocellular carcinoma in patients undergoing liver resection and liver transplantation. J Gastrointest Surg. 2008;12:718–24.CrossRefPubMed
Metadata
Title
Sarcomatoid hepatocellular carcinoma (SHC): a case report
Authors
Yingying Yu
Yanping Zhong
Jingyu Wang
Di Wu
Publication date
01-12-2017
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2017
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-017-1286-1

Other articles of this Issue 1/2017

World Journal of Surgical Oncology 1/2017 Go to the issue